Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
APGE 
Apogee Therapeutics, Inc. Common Stock (APGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: APGE (3-star) is a STRONG-BUY. BUY since 70 days. Simulated Profits (98.04%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $103.14
1 Year Target Price $103.14
| 9 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 211.68% | Avg. Invested days 42 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.29B USD | Price to earnings Ratio - | 1Y Target Price 103.14 |
Price to earnings Ratio - | 1Y Target Price 103.14 | ||
Volume (30-day avg) 9 | Beta 1.42 | 52 Weeks Range 26.20 - 80.99 | Updated Date 01/9/2026 |
52 Weeks Range 26.20 - 80.99 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.38 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.26% | Return on Equity (TTM) -38.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4776015342 | Price to Sales(TTM) - |
Enterprise Value 4776015342 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 54833587 | Shares Floating 48655647 |
Shares Outstanding 54833587 | Shares Floating 48655647 | ||
Percent Insiders 6.19 | Percent Institutions 113 |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2020. It is focused on discovering, developing, and commercializing novel antibody-based therapies for serious and unmet medical needs. The company's initial focus is on inflammatory and autoimmune diseases.
Core Business Areas
- Immunology: Apogee Therapeutics is developing novel antibody therapies targeting specific pathways involved in inflammatory and autoimmune diseases. Their lead programs are designed to address significant unmet needs in conditions such as atopic dermatitis, psoriasis, and ulcerative colitis.
Leadership and Structure
Apogee Therapeutics is led by a team of experienced biotechnology professionals. Key leadership includes the Chief Executive Officer, Chief Medical Officer, and Chief Scientific Officer, supported by a broader management team and a Board of Directors with expertise in drug development and the pharmaceutical industry.
Top Products and Market Share
Key Offerings
- APG001: A novel antibody targeting IL-13, currently in clinical development for atopic dermatitis and other inflammatory conditions. Competitors include companies with approved IL-13 inhibitors or those developing similar novel biologics. Market share data is not yet applicable as the product is in clinical trials.
- APG002: Another novel antibody therapy, targeting a different pathway implicated in inflammatory diseases. Details on its specific target and indication are evolving as it progresses through preclinical and early clinical stages. Competitors will depend on the specific target and indication identified. Market share data is not applicable.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the immunology and autoimmune disease segment, is characterized by significant innovation, high research and development costs, and a competitive landscape. There is a strong demand for novel therapies that offer improved efficacy, safety, and patient convenience.
Positioning
Apogee Therapeutics positions itself as a developer of differentiated antibody-based therapies by focusing on novel targets and mechanisms of action. Their strategy aims to address unmet needs in significant disease areas, leveraging their expertise in antibody engineering and clinical development.
Total Addressable Market (TAM)
The total addressable market for inflammatory and autoimmune diseases is substantial, running into tens of billions of dollars globally. Apogee Therapeutics is positioned to capture a portion of this market with its pipeline candidates, assuming successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Experienced leadership team with a track record in drug development.
- Proprietary antibody discovery and engineering platform.
- Focus on significant unmet medical needs in large markets.
- Strong investor backing.
Weaknesses
- Early-stage company with no approved products.
- High R&D costs and inherent risks in drug development.
- Reliance on future clinical trial success.
- Limited brand recognition compared to established players.
Opportunities
- Significant unmet needs in target disease areas.
- Potential for partnerships or licensing agreements.
- Advancements in understanding disease pathways.
- Expansion of pipeline to other indications or diseases.
Threats
- Clinical trial failures or delays.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Regulatory hurdles and delays.
- Pricing pressures and reimbursement challenges.
- Emergence of alternative treatment modalities.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Sanofi (SNY)
- Regeneron Pharmaceuticals, Inc. (REGN)
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
Competitive Landscape
Apogee Therapeutics operates in a highly competitive landscape with established pharmaceutical giants and numerous other biotechnology companies. Its competitive advantage will stem from the potential novelty and efficacy of its drug candidates, targeting specific patient populations with unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Apogee Therapeutics is in its early stages of growth, with its trajectory primarily defined by its progress in clinical development and the expansion of its research pipeline.
Future Projections: Future growth is projected to be driven by the successful advancement of its lead drug candidates through clinical trials, potential regulatory approvals, and subsequent commercialization. Analyst projections will focus on the potential market size for its pipeline drugs.
Recent Initiatives: Key recent initiatives include advancing its lead candidates into clinical trials, expanding its research team, and securing necessary funding through equity offerings.
Summary
Apogee Therapeutics is a promising clinical-stage biotech firm with a strong focus on innovative antibody therapies for inflammatory and autoimmune diseases. Its experienced team and novel platform are key strengths, but it faces significant risks inherent in drug development and intense market competition. Success hinges on the efficacy and safety of its pipeline candidates progressing through clinical trials and navigating regulatory pathways.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Filings (SEC)
- Industry Analyst Reports
- Financial News Outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. All data is based on publicly available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 | |||
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.